Last reviewed 2026-06-02 · How we verify

DA-1229_01

Dong-A ST Co., Ltd. · Phase 1 active Small molecule ✓ Verified Jun 2026

DA-1229_01 is a Small molecule drug developed by Dong-A ST Co., Ltd.. It is currently in Phase 1 development. Also known as: Evogliptin/Metformin XR 5/1000 mg, Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets.

DA-1229_01 is a small molecule being studied for its pharmacokinetics and safety profiles in healthy subjects and individuals with type 2 diabetes. The study, NCT05739903, is an open-label, randomized, single-dose, cross-over, two-group study evaluating DA-1229_01 5/1000mg in healthy subjects at a fasting state.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DA-1229_01
Also known as	Evogliptin/Metformin XR 5/1000 mg, Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets
Sponsor	Dong-A ST Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DA-1229_01 CI brief — competitive landscape report
DA-1229_01 updates RSS · CI watch RSS
Dong-A ST Co., Ltd. portfolio CI

Frequently asked questions about DA-1229_01

What is DA-1229_01?

DA-1229_01 is a Small molecule drug developed by Dong-A ST Co., Ltd..

Who makes DA-1229_01?

DA-1229_01 is developed by Dong-A ST Co., Ltd. (see full Dong-A ST Co., Ltd. pipeline at /company/dong-a-st-co-ltd).

Is DA-1229_01 also known as anything else?

DA-1229_01 is also known as Evogliptin/Metformin XR 5/1000 mg, Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets.

What development phase is DA-1229_01 in?

DA-1229_01 is in Phase 1.

Manufacturer: Dong-A ST Co., Ltd. — full pipeline
Also known as: Evogliptin/Metformin XR 5/1000 mg, Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing